FDA
-
-
-
-
-
-
-
Lantheus' LNTH-2513 (18F-GP1) PET/CT Awarded SNMMI’s Image of the Year
-
-
-
-
-
-
-
Lantheus Announces FDA Approval of PYLARIFY TruVu™ (piflufolastat F 18) Injection
-
-
-
-
-
-
-
Lantheus Reports Third Quarter 2025 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Lantheus and GE HealthCare Announce Exclusive Licensing Agreement for Prostate Cancer Imaging Agent PYLARIFY® (Piflufolastat F 18) in Japan
-
-
-
-
-
-
-
Lantheus Completes Acquisition of Life Molecular Imaging and Appoints Dr. Ludger Dinkelborg as Head of R&D
-
-
-
-
-
-
-
Lantheus Announces Alzheimer’s Disease Radiodiagnostic MK-6240 Meets Co-Primary Endpoints in Two Pivotal Studies
-
-
-
-
-
-
-
Lantheus Continues to Commend CMS’ CY25 Rule to Enhance Payment for Specialized Diagnostic Radiopharmaceuticals and Reaffirms Outlook for PYLARIFY’s Blockbuster Status for 2025
-
325,890 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

